- Evaluate the rationale used by those who would recommend genetic testing of railroad workers engaged in track management who have carpal tunnel syndrome (CTS).
- Describe the probable respective contributions of physical/environmental and genetic factors in railroad track workers with CTS.
- Discuss the medical, social, and ethical issues raised by testing railroad track workers for genetic mutations and deletions.
In 2000, approximately 20 railroad track workers who filed injury reports or compensation claims for carpal tunnel syndrome were tested by their employer for two genetic traits to determine the work relatedness of the condition. The testing involved deletions, variants, or mutations in the genetic coding for peripheral myelin protein (PMP22) and transthyretin (TTR). This article is an assessment of whether there is a scientific basis for such testing. A review of the scientific literature indicated that neither the scientific basis nor the population validity of the PMP22 or TTR tests for carpal tunnel syndrome were adequately established before use on railroad track workers in 2000. Although ethical and legal issues may predominate in this case, the absence of a compelling scientific basis undermines the decision to conduct the tests.
From the National Institute for Occupational Safety and Health, Centers for Disease Control and Prevention, Cincinnati, Ohio (Dr Schulte); and University of California at Berkeley, School of Public Health, Center for Occupational and Environmental Health, Berkeley, California (Dr Lomax).
Address correspondence to: P.A. Schulte, NIOSH, MS-C14, 4676 Columbia Pkwy, Cincinnati, OH 45226; e-mail: firstname.lastname@example.org.
Paul A. Schulte and Geoffrey Lomax have no commercial interest related to this article.
This article was co-written by an officer or employee of the US Government as part of his official duties and is therefore not subject to US copyright.